CONMED (CNMD) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Sales: $343.5 million, up 0.3% year-over-year (0.5% decrease on a constant currency basis). Organic growth was 6%.

Adjusted EPS: $1.38, a 20% increase year-over-year, benefiting from a $0.21 tariff refund.

Adjusted Gross Margin: 59.5%, up 300 basis points, primarily due to tariff refunds.

Free Cash Flow: $34.2 million, a 46% increase year-over-year.

Total Debt: $834.2 million, with a leverage ratio of 2.9x.

Share Repurchases: Approximately 1 million shares repurchased for $43.7 million in the first half of 2026.

2Strategic Updates and Business Highlights

Product Line Performance:

General Surgery: Sales grew 5.3% organically, driven by AirSeal and Buffalo Filter.

AirSeal: Continued focus on adoption in robotic and laparoscopic surgeries, with a new indication for use with Intuitive's 8mm Hex cannulas.

Buffalo Filter: Strong growth in direct smoke evacuation products, supported by new legislation in Michigan and Maryland.

Orthopedic Surgery: Sales increased 6.8% overall, with international sales up 10.8%. Domestic sales were flat, attributed to strategic organizational changes.

Operational Progress:

Completed exit from gastroenterology product offerings, enhancing focus on core markets.

Improved supply chain stability and reduced back orders.

Strengthened leadership team with new appointments, including CFO John Gallagher.

3Forward Guidance and Outlook

2026 Revenue Guidance: Updated to reflect organic constant currency growth of 5% to 6%. Full-year GI revenue expected to be $20 million to $22 million.

Adjusted EPS Guidance: Revised to $4.48 to $4.60, up from $4.30 to $4.45, reflecting better-than-expected Q2 results and share repurchase activity.

Q3 Expectations: GAAP net sales projected between $334 million and $339 million, with organic growth of 6.4% to 7.6%.

4Bad News, Challenges, or Points of Concern

AirSeal Growth: Growth was lower than expected, with the company anticipating a slower pace of improvement in the second half of 2026.

Domestic Orthopedic Sales: Flat performance in the U.S. raised concerns about the effectiveness of recent strategic changes.

Free Cash Flow Decline: Down about $20 million year-over-year primarily due to working capital issues, although management is focused on improving this.

Interest Expense Increase: Adjusted interest expense rose to $6.8 million, with expectations of further increases due to refinancing activities.

5Notable Q&A Insights

AirSeal Performance: Management acknowledged below-expected growth but remains confident in long-term high single-digit to low double-digit growth.

BioBrace RC Penetration: Strong uptake noted, with consistent use by surgeons leading to durable relationships.

Surgical Volumes: Management reported no significant changes in surgical volumes, maintaining a positive outlook despite external concerns.

International Growth: Strong performance attributed to similar growth drivers as in the U.S., with optimism for continued momentum despite potential challenges from distributor dynamics. Overall, CONMED's Q2 2026 results reflect a mix of strong performance in certain areas, strategic advancements, and some challenges, particularly with AirSeal and domestic orthopedic sales. The company remains focused on long-term growth and value creation.